BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Piramal Pharma Ltd. Share Price

NSE
BSE

NSE : PPLPHARMA

BSE : 543635

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹165.10

High

₹196.44

Price Summary

Previous Close ₹183.73
Day's Range ₹165.10 - ₹196.44
Open ₹166.70
52 Week Range ₹132.30 - ₹226.00
Volume 5,12,82,284
Market Cap ₹0.02
Previous Close ₹183.85
Day's Range ₹165.10 - ₹196.40
Open ₹168.00
52 Week Range ₹132.50 - ₹226.00
Volume 16,29,473
Market Cap ₹0.02

Stocks Summary

Trade Value ( ₹ in Lacs) 94,220.94
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -2.45
P/E Ratio 326.26
Book Value(₹) 2.69
PAT Margin (%) 0.86
Face Value (₹) 10.00
ROCE(%) 6.61
Trade Value ( ₹ in Lacs) 2,995.79
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.00
Price/Earning (TTM) 0.00
TTM EPS (₹) -2.45
P/E Ratio 326.26
Book Value(₹) 2.69
PAT Margin (%) 0.86
Face Value (₹) 10.00
ROCE(%) 6.61

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 52857.1 27540.7
Expenses N/A N/A
PBT 9111.4 2728.0
Operating profit 0.0 0.0
Net profit 6914.0 1535.0

Shareholding Pattern

Promoters (% Holding)

34.86%

Mutual funds (% Holding)

14.12%

Non-Institution (% Holding)

19.36%

FI/Banks/Insurance (% Holding)

1.24%

Government (% Holding)

0.00%

FII

30.17%

About Piramal Pharma Ltd.

Founded 2020
NSE Symbol PPLPHARMA

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,43,972.94 1,831.30 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,78,025.88 6,681.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,47,477.60 4,351.60 3,101.60 - 3,101.60
Lupin Ltd. 1,11,668.12 2,460.50 1,836.80 - 1,836.80
Apollo Hospitals Enterprise Ltd. 1,11,526.57 7,820.45 6,677.50 - 6,677.50
Cipla Ltd. 1,10,282.52 1,361.00 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,09,381.80 1,307.00 1,138.50 - 1,138.50
Max Healthcare Institute Ltd. 98,852.37 1,015.10 903.00 - 903.00
Mankind Pharma Ltd. 97,505.92 2,375.40 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 94,495.43 940.10 835.50 - 835.50
no-content No Records Found

Latest News

Apr
13
2026
EQUITY Posted on Apr 13th 2026

Piramal Pharma informs about updates

With reference to it letter dated 11th December, 2025 regarding US FDA Inspection at company’s manufacturing facility located at Lexington, (Kentucky, USA). Piramal Pharma has informed that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection. The intimation is being submitted today being the first working day after receipt of the said EIR.
The above information is a part of company’s filings submitted to BSE.  
Read More
Mar
21
2026
EQUITY Posted on Mar 21st 2026

Piramal Pharma informs about ESG ratings

Piramal Pharma has informed that as per the information received by the Company on March 20, 2026, SES ESG Research (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘68.5’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year. The link for the rating as published is also available on the website. The Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company. This intimation is also being uploaded on the website of the Company at https://www.piramalpharma.com/.

The above information is a part of company’s filings submitted to BSE.

Read More
May
7
2026
EQUITY Posted on May 7th 2026

Global Longlife Hospital and Research informs about outcome of board meeting

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Global Longlife Hospital and Research has informed that in the Board Meeting held today on Thursday, May 07, 2026, the Board of Directors of the Company has considered and approved the following matters: 1. Audited Financial Results for the Half Year and Year ended March 31, 2026 along with the Audit Report. 2. Alteration of name clause of Memorandum of Association of the company from Global Longlife Hospital and Research to Kanzi Enterprise or Asahi Enterprise or Siddhaa Enterprise, subject to the approval of shareholders of the company and ministry of corporate affairs. 3. Alteration in Clause III (A): the Main Object Clause of Memorandum of Association (‘MOA’) of the Company, subject to approval of Members. (The existing Clause III (A) will be deleted representing health care industry and new Clause III (A) will be added representing trade and service industry). The above matter has been duly approved by the Board of Directors at their meeting which commenced at 02:00 pm and concluded at 03:45 pm. The company has informed that, R B Gohil & Co., Chartered Accountants, Statutory Auditors have issued their Audit Reports with unmodified opinion on Audited Financial Results for the year ended March 31, 2026. In this connection, it has enclosed Audited Financial Results for the Half year and Year ended on March 31, 2026, Audit Report and the declaration that Auditor's Report on the results is with unmodified opinion (as Annexure-1). The same will be made available on the Company's website www.globalhospital.co.in.
The above information is a part of company’s filings submitted to BSE.
Read More
May
7
2026
EQUITY Posted on May 7th 2026

Panacea Biotec informs about updates

Panacea Biotec has informed that it enclosed details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The above information is a part of company’s filings submitted to BSE.
Read More
May
7
2026
EQUITY Posted on May 7th 2026

Kilitch Drugs India informs about board meeting

Kilitch Drugs India has informed that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended 31st March, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Piramal Pharma Ltd. ?

The current share price of Piramal Pharma Ltd. is ₹183.73 as of 2026-05-07.

The market capitalisation of Piramal Pharma Ltd. is ₹21,945.89 as of 2026-05-06.

The 1-year return of Piramal Pharma Ltd. is 0.00% as of 2026-05-07.

The P/E ratio of Piramal Pharma Ltd. is 326.26 as of 2026-05-07.

The 52-week high and low of Piramal Pharma Ltd. are ₹226.00 and ₹132.30, respectively, as of 2026-05-07.

The dividend yield of Piramal Pharma Ltd. is 0.0% as of2026-05-06.

You can buy Piramal Pharma Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Piramal Pharma Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

What types of healthcare offerings and products are manufactured by Piramal Pharma Ltd.?

Piramal Pharma Ltd. manufactures a range of complex hospital generics, including inhalation anesthetics and injectables. The company also offers a line of consumer healthcare products and provides comprehensive contract development and manufacturing services (CDMO) for global firms.

Piramal Pharma Ltd. establishes partnerships by offering extensive CDMO services, acting as an integrated manufacturing partner for global pharmaceutical innovators. The firm also partners directly with major healthcare institutions to supply hospital generics and complex anesthesia products.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Personal Loan
My Accounts
My Accounts
Explore
Explore